CEPI is an innovative global partnership between public, private, philanthropic and civil society organisations.

As of December 2018, CEPI has secured more than USD $747 million towards its USD $1 billion funding target, with financial support provided by the Bill & Melinda Gates Foundation, the Wellcome Trust, the European Commission, and the governments of Australia, Belgium, Canada, Germany, Japan, Norway, and the UK (Figure 1).

These funds are used to finance CEPI’s core activities in coordinating efforts and investing in the development of new vaccines and technologies to prevent and contain infectious disease epidemics.

Since CEPI’s launch in January 2017, three Call for Proposals (CfPs) have been issued. The first CfP is for candidate vaccines against MERS–CoV, and Nipah and Lassa viruses. The second CfP supports the development of platforms that can be used for rapid vaccine development against unknown pathogens. The third CfP is for candidate vaccines against Rift Valley fever and Chikungunya.

The calls have received applications from a range of biotech firms, academic institutions, non-profit organisations, and pharmaceutical companies. As of December 2018, CEPI has signed eight partnership agreements for the development of vaccine candidates against our priority diseases as well as the development of platform technologies.

To address the critical knowledge gaps and tools needed for rational and accelerated vaccine development, and future access to a licensed product, CEPI has also set up an enabling sciences programme. This has included a partnership to enhance Lassa fever diagnostics, as well as partnerships to develop biological standards and assays.

In 2018, CEPI’s total expenditure was USD $49 million. In the 2019 budget, the expenditure is expected to reach USD $187 million due to the commitments to partners taking effect (Figure 2).

CEPI’s business plan has a target of funds of USD $1 billion. For the period 2017–2022, CEPI is tracking a shortfall of funds of USD $104 million up to the end of 2022 (Figure 3). CEPI is working on filling this gap, and currently has several pending proposals from donors.

All figures reported in this document are correct as of December 2018.
Figure 1) Funding received/pledged 2017-2022 (MUSD 747)

European Commission; 13.4 %
Government of UK; 1.7 %
Government of Canada; 0.9 %
Government of Belgium; 0.4 %
Government of Australia; 0.2 %
Government of Japan; 16.7 %
Federal Government of Germany; 13.7 %
Government of Norway; 26.5 %
Wellcome; 13.4 %
Bill and Melinda Gates Foundation; 13.4 %

Figure 2) Expenditure 2017-2022

Investment costs

<table>
<thead>
<tr>
<th>Year</th>
<th>Investment costs</th>
<th>Resource mobilisation costs</th>
<th>Administration costs</th>
<th>Financial costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 3) Funds and expenditure 2017-2022

Legend:
- Carried over from previous year
- Total funds received for the year
- Total expenditure for the year